PEDIATRIX MEDICAL GROUP INC (MD) Stock Fundamental Analysis
NYSE:MD - New York Stock Exchange, Inc. - US58502B1061 - Common Stock - Currency: USD
Taking everything into account, MD scores 5 out of 10 in our fundamental rating. MD was compared to 103 industry peers in the Health Care Providers & Services industry. Both the profitability and the financial health of MD get a neutral evaluation. Nothing too spectacular is happening here. A decent growth rate in combination with a cheap valuation! Better keep an eye on MD.
1. Profitability
1.1 Basic Checks
In the past year MD was profitable.
In the past year MD had a positive cash flow from operations.
In multiple years MD reported negative net income over the last 5 years.
Each year in the past 5 years MD had a positive operating cash flow.
1.2 Ratios
MD has a Return On Assets of -4.13%. This is in the lower half of the industry: MD underperforms 65.05% of its industry peers.
The Return On Equity of MD (-10.44%) is worse than 61.16% of its industry peers.
MD has a Return On Invested Capital of 9.08%. This is in the better half of the industry: MD outperforms 78.64% of its industry peers.
The Average Return On Invested Capital over the past 3 years for MD is in line with the industry average of 9.71%.
The 3 year average ROIC (7.83%) for MD is below the current ROIC(9.08%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROIC | 9.08% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
1.3 Margins
MD's Operating Margin of 10.02% is amongst the best of the industry. MD outperforms 80.58% of its industry peers.
MD's Operating Margin has declined in the last couple of years.
MD does not have Profit Margin and Gross Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), MD is creating some value.
MD has more shares outstanding than it did 1 year ago.
MD has more shares outstanding than it did 5 years ago.
The debt/assets ratio for MD is higher compared to a year ago.
2.2 Solvency
An Altman-Z score of 1.87 indicates that MD is not a great score, but indicates only limited risk for bankruptcy at the moment.
MD has a Altman-Z score (1.87) which is in line with its industry peers.
The Debt to FCF ratio of MD is 3.15, which is a good value as it means it would take MD, 3.15 years of fcf income to pay off all of its debts.
MD has a better Debt to FCF ratio (3.15) than 75.73% of its industry peers.
A Debt/Equity ratio of 0.75 indicates that MD is somewhat dependend on debt financing.
The Debt to Equity ratio of MD (0.75) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Altman-Z | 1.87 |
ROIC/WACC1.11
WACC8.21%
2.3 Liquidity
A Current Ratio of 1.81 indicates that MD should not have too much problems paying its short term obligations.
MD has a better Current ratio (1.81) than 66.02% of its industry peers.
MD has a Quick Ratio of 1.81. This is a normal value and indicates that MD is financially healthy and should not expect problems in meeting its short term obligations.
MD has a Quick ratio of 1.81. This is in the better half of the industry: MD outperforms 67.96% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 31.71% over the past year.
MD shows a very negative growth in Earnings Per Share. Measured over the last years, the EPS has been decreasing by -15.01% yearly.
MD shows a decrease in Revenue. In the last year, the revenue decreased by -1.13%.
MD shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 2.49% yearly.
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
3.2 Future
MD is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 1.39% yearly.
The Revenue is expected to grow by 2.24% on average over the next years.
EPS Next Y14.57%
EPS Next 2Y8.65%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
MD is valuated reasonably with a Price/Earnings ratio of 8.10.
Based on the Price/Earnings ratio, MD is valued cheaper than 96.12% of the companies in the same industry.
MD is valuated cheaply when we compare the Price/Earnings ratio to 27.30, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.46 indicates a rather cheap valuation of MD.
Compared to the rest of the industry, the Price/Forward Earnings ratio of MD indicates a rather cheap valuation: MD is cheaper than 94.17% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of MD to the average of the S&P500 Index (21.76), we can say MD is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.1 | ||
| Fwd PE | 7.46 |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, MD is valued cheaply inside the industry as 88.35% of the companies are valued more expensively.
MD's Price/Free Cash Flow ratio is rather cheap when compared to the industry. MD is cheaper than 92.23% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 5.8 | ||
| EV/EBITDA | 6.36 |
4.3 Compensation for Growth
The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)0.56
PEG (5Y)N/A
EPS Next 2Y8.65%
EPS Next 3Y6.79%
5. Dividend
5.1 Amount
No dividends for MD!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
13.12
-0.38 (-2.81%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners91.66%
Inst Owner Change0%
Ins Owners1.89%
Ins Owner Change5.91%
Market Cap1.13B
Analysts78.75
Price Target17.49 (33.31%)
Short Float %2.58%
Short Ratio2.37
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.85%
Min EPS beat(2)32.73%
Max EPS beat(2)34.96%
EPS beat(4)4
Avg EPS beat(4)22.2%
Min EPS beat(4)5.21%
Max EPS beat(4)34.96%
EPS beat(8)5
Avg EPS beat(8)6.83%
EPS beat(12)5
Avg EPS beat(12)1.12%
EPS beat(16)9
Avg EPS beat(16)4.81%
Revenue beat(2)1
Avg Revenue beat(2)-0.56%
Min Revenue beat(2)-1.44%
Max Revenue beat(2)0.31%
Revenue beat(4)1
Avg Revenue beat(4)-1.2%
Min Revenue beat(4)-3.14%
Max Revenue beat(4)0.31%
Revenue beat(8)1
Avg Revenue beat(8)-2.7%
Revenue beat(12)1
Avg Revenue beat(12)-3.01%
Revenue beat(16)3
Avg Revenue beat(16)-2.21%
PT rev (1m)-5.14%
PT rev (3m)-6.61%
EPS NQ rev (1m)-0.59%
EPS NQ rev (3m)2.35%
EPS NY rev (1m)1.77%
EPS NY rev (3m)7.48%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0.53%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0.52%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 8.1 | ||
| Fwd PE | 7.46 | ||
| P/S | 0.57 | ||
| P/FCF | 5.8 | ||
| P/OCF | 5.26 | ||
| P/B | 1.43 | ||
| P/tB | N/A | ||
| EV/EBITDA | 6.36 |
EPS(TTM)1.62
EY12.35%
EPS(NY)1.76
Fwd EY13.41%
FCF(TTM)2.26
FCFY17.24%
OCF(TTM)2.49
OCFY19.02%
SpS23
BVpS9.19
TBVpS-5.4
PEG (NY)0.56
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.13% | ||
| ROE | -10.44% | ||
| ROCE | 11.5% | ||
| ROIC | 9.08% | ||
| ROICexc | 10.41% | ||
| ROICexgc | 62.51% | ||
| OM | 10.02% | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | 9.83% |
ROA(3y)-1.5%
ROA(5y)-4.7%
ROE(3y)-4.21%
ROE(5y)-20.91%
ROIC(3y)7.83%
ROIC(5y)7.13%
ROICexc(3y)8.94%
ROICexc(5y)8.89%
ROICexgc(3y)78.23%
ROICexgc(5y)75.12%
ROCE(3y)9.91%
ROCE(5y)9.03%
ROICexcg growth 3Y26.95%
ROICexcg growth 5Y24.1%
ROICexc growth 3Y3.64%
ROICexc growth 5Y14.51%
OM growth 3Y-7.13%
OM growth 5Y-6.94%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.75 | ||
| Debt/FCF | 3.15 | ||
| Debt/EBITDA | 2.62 | ||
| Cap/Depr | 73.43% | ||
| Cap/Sales | 1.01% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 95.15% | ||
| Profit Quality | N/A | ||
| Current Ratio | 1.81 | ||
| Quick Ratio | 1.81 | ||
| Altman-Z | 1.87 |
F-Score5
WACC8.21%
ROIC/WACC1.11
Cap/Depr(3y)81.28%
Cap/Depr(5y)89.11%
Cap/Sales(3y)1.42%
Cap/Sales(5y)1.52%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)31.71%
EPS 3Y-2.95%
EPS 5Y-15.01%
EPS Q2Q%65%
EPS Next Y14.57%
EPS Next 2Y8.65%
EPS Next 3Y6.79%
EPS Next 5Y1.39%
Revenue 1Y (TTM)-1.13%
Revenue growth 3Y1.74%
Revenue growth 5Y2.49%
Sales Q2Q%-7.42%
Revenue Next Year-6.17%
Revenue Next 2Y-1.57%
Revenue Next 3Y0.53%
Revenue Next 5Y2.24%
EBIT growth 1Y30.12%
EBIT growth 3Y-5.51%
EBIT growth 5Y-4.62%
EBIT Next Year41.08%
EBIT Next 3Y15.15%
EBIT Next 5YN/A
FCF growth 1Y45.08%
FCF growth 3Y60.68%
FCF growth 5Y-11.42%
OCF growth 1Y31.09%
OCF growth 3Y39.11%
OCF growth 5Y-10.4%